An Industry Roundtable Moderated by Patricia Van Arnum and Rich Whitworh. Contract service and technology providers share their perspectives on the influence of quality by design in the expectations ...
Industry experts discuss the application, challenges, and benefits of a quality-by-design approach to sterile manufacturing. To gain perspective on the implementation of quality by design (QbD) in ...
In the past 10 years, the pharmaceutical industry has been moving towards a design space approach to development and manufacture – an approach that has been defined by ICHQ8, Q9 and Q10, and the ...
As the regulatory authorities the world over are demanding that manufacturers should design quality into products at every stage of development and manufacture, the use of Quality by design (QbD) has ...
The FDA’s Quality by Design (QbD) initiative, part of the larger Process Analytical Technology (PAT) effort, will require an enormous undertaking by companies that plan to employ its principles. The ...
The pharmaceutical industry is implementing Quality by Design (QbD) and Process Analytical Technology (PAT) more and more, making their symbiotic nature even more obvious. PAT and QbD are catalysts ...
Global regulatory authorities continue to push Quality-by-Design (QbD) in pharmaceutical development to support risk management. While QbD affords many important long-term benefits, these expectations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results